Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Glioma 1Chondrosarcoma 1Cholangiocarcinoma 1Breast Neoplasms 1Blast Crisis 1Anemia 1

Interventions

Magnetic Resonance Spectroscopy 11Specimen Handling 8X-Rays 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 6olaparib 4ulixertinib 3trametinib 3palbociclib 3larotrectinib 3ivosidenib 3erdafitinib 3dabrafenib 3Vemurafenib 3tipifarnib 2tazemetostat 2selpercatinib 2ensartinib 2durvalumab 2Nivolumab 2LY3023414 2Gemcitabine 2Doxorubicin 2Docetaxel 2Cisplatin 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1sonidegib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × enasidenib × Gastrointestinal × Clear all
NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Celgene

Phase 1/2 Completed
21 enrolled 33 charts
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡